Novo Nordisk's CagriSema Shows 25% Weight Loss in Phase 3 Clinical Trial
Novo Nordisk announced promising results from a post hoc analysis of its Phase 3 clinical trial for CagriSema, a next-generation obesity drug combining semaglutide and cagrilintide. The study revealed that women participating in the trial experienced an average weight loss of nearly 25% over 68 weeks, significantly outperforming the placebo group's 3% loss. While these results are highly competitive—surpassing the efficacy seen in Novo Nordisk's own Wegovy (approximately 15%)—they remain slightly behind Eli Lilly’s Zepbound, which achieved nearly 21% in pivotal trials and up to 26% in head-to-head comparisons. The data provides a potential boost to Novo Nordisk's pipeline as it faces intensifying competition in the lucrative weight-loss market.